Sun Pharma gains after receiving USFDA nod for generic drug

Image
Capital Market
Last Updated : Jul 28 2016 | 12:07 AM IST

Sun Pharmaceutical Industries rose 0.87% to Rs 789 at 12:15 IST on BSE after the company announced that one of its subsidiaries received final approval from the US drug regulator for generic version of Crestor.

The announcement was made during market hours today, 20 July 2016.

Meanwhile, the BSE Sensex was up 388.78 points, or 1.43%, to 27,515.68.

On BSE, so far 55,127 shares were traded in the counter, compared with average daily volume of 2.89 lakh shares in the past one quarter. The stock hit a high of Rs 789.60 and a low of Rs 782 so far during the day. The stock hit a 52-week high of Rs 965.15 on 20 August 2015. The stock hit a 52-week low of Rs 706.40 on 24 November 2015. The stock had outperformed the market over the past one month till 19 July 2016, gaining 5.3% compared with 4.36% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, dropping 6.52% as against Sensex's 7.64% rise.

The large-cap company has an equity capital of Rs 240.68 crore. Face value per share is Re 1.

Sun Pharmaceutical Industries announced that one of its subsidiaries received final approval from United States Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for generic version of Crestor, Rosuvastatin Calcium tablets 5 mg (base), 10 mg (base), 20 mg (base) and 40 mg (base).

Rosuvastatin Calcium tablets are therapeutic equivalents of IPR Pharmaceuticals, Inc.'s Crestor tablets. As per IMS MAT May 2016 data, these tablets have annual sales of approximately $6.8 billion in the US. These tablets are indicated for the treatment of adult patients with Hypertriglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) and adult patients with Homozygous Familial Hypercholesterolemia.

Sun Pharmaceutical Industries' (Sun Pharma) consolidated net profit rose 92.7% to Rs 1713.69 crore on 21.5% growth in net sales to Rs 7413.87 crore in Q4 March 2016 over Q4 March 2015.

Sun Pharmaceutical Industries is a specialty generic pharmaceutical company and India's top pharmaceutical company.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 20 2016 | 12:08 PM IST

Next Story